Trial Profile
A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Metformin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Oct 2013 Interim results (n=55) presented at the 15th World Conference on Lung Cancer
- 16 May 2012 Planned End Date changed to 2 May 2013.
- 16 May 2012 New trial record